Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna is a clinical-stage biotechnology company with a strong pipeline in endocrinology, immunology and inflammation, and metabolic disease. Key recent developments have been the discontinuation of their Ph2b CSU study of their MRGPRX2 inhibitor, EVO756, which did not meet primary endpoint, and the initiation of a Phase 1 trial for their potent oral small molecule PTH1R agonist for hypoparathyroidism, SEP-479. Risks include potential delays in R&D or commercial development and the emergence of surprise competitors. However, with increasing physician and patient enthusiasm for novel PTH treatments and the potential for once-daily dosing with SEP-479, the company has upside potential and a BUY rating.

Bears say

Septerna is a clinical-stage biotechnology company with a shaky track record, evidenced by their recent competitor failures and their own struggles with CSU trials. They are heavily reliant on their proprietary Native Complex Platform, which has yet to yield any successful drugs on the market. Additionally, their financial outlook is not promising, with a projected revenue of only $0.74B in 2040 and a high risk of dilution for investors.

Septerna Inc (SEPN) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.